Health Care & Life Sciences » Biotechnology | Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
52.21 M
Public Float
43.14 M
Supernus Pharmaceuticals Inc.
Stock Exchange NASDAQ Stock Market
EPS
$1.9
Market Cap
$1.71 B
Shares Outstanding
52.38 M
Public Float
50.58 M

Profile

Address
1550 East Gude Drive
Rockville Maryland 20850
United States
Employees -
Website http://www.supernus.com
Updated 07/08/2019
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder.

Financials

View All

Charles W. Newhall
Chairman
Jack A. Khattar
President, CEO, Secretary & Director